# FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT06609928** · PHASE1 · RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 12 (estimated)

## Conditions studied

- Recurrent Childhood Acute Myeloid Leukemia
- Refractory Childhood Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** FOLR1 CAR T-cells
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Echocardiography Test
- **DRUG:** Fludarabine
- **PROCEDURE:** Pheresis
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT06609928
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-24
- **Primary completion:** 2027-10-01
- **Final completion:** 2042-10-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06609928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06609928, "FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06609928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*